Ambalal Sarabhai Enterprises is locked at upper circuit limit of Rs. 19.95, up by 0.95 points or 5.00% from its previous closing of Rs. 19.00 on the BSE.
The scrip opened at Rs. 19.95 and has touched a high and low of Rs. 19.95 and Rs. 19.95 respectively.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 21.60 on 10-Jan-2020 and a 52 week low of Rs. 9.05 on 16-Oct-2019.
Last one week high and low of the scrip stood at Rs. 19.95 and Rs. 17.15 respectively. The current market cap of the company is Rs. 145.60 crore.
The promoters holding in the company stood at 30.76%, while Institutions and Non-Institutions held 0.01% and 69.23% respectively.
CoSara Diagnostics (CoSara), a Joint Venture (JV) company of Synbiotics, a wholly owned subsidiary of Ambalal Sarabhai Enterprises and CoDiagnostics Inc, USA, has started the import and marketing of COVID-19, RT-PCR test kits in India based upon the license granted by CDSCO. CoSara will be marketing pan India the US FDA and CE approved kits of its joint venture partner CoDiagnostics Inc, USA.
Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1517.90 |
Dr. Reddys Lab | 6362.00 |
Cipla | 1478.90 |
Zydus Lifesciences | 1066.95 |
Lupin | 1614.95 |
View more.. |